QUILTY EDWARD J Form SC 13D/A June 15, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 9)*

Derma Sciences, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value

(Title of Class of Securities)

249827205

(CUSIP Number)
Raymond C. Hedger
Hedger & Hedger

2 Fox Chase Drive, P.O. Box 915, Hershey, PA 17033 (717)534-9993

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 10, 2004

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement of Schedule 13G to report the acquisition which is the subject of the Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), ss. 240.13d-1(f) or ss. 240.13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

PAGE 2 CUSIP		Schedule 13D		
	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON			
	Edward J. Quilty 101-42-3117			
2 C	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*	(a) [] (b) []		
3 S	SEC USE ONLY			
4 S	SOURCE OF FUNDS* Not applicable			
5 I	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PUTEMS 2(d) OR 2(e)	RSUANT TO		
6 C	CITIZENSHIP OR PLACE OF ORGANIZATION			
	United States			
NUM	BER OF SHARES 7 SOLE VOTING POWER			
В	BENEFICALLY 919,740			
OW	NNED BY EACH 8 SHARED VOTING POWER			
	REPORTING			
 PERSON	WITH 9 SOLE DISPOSITIVE POWER 919,740			
	10 SHARED DISPOSITIVE POWER			
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 919,740			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAI	 N SHARES*		
		[]		
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)			
	9.10%			
14	TYPE OF REPORTING PERSON*			
	IN			
	*SEE INSTRUCTIONS BEFORE FILL	 ING OUT!		

PAGE 3

CUSIP No. 249827205

Schedule 13D

Item 1. Security and Issuer

This Schedule 13D relates to the common stock, \$.01 par value (the "Common Stock"), of Derma Sciences, Inc., a Pennsylvania corporation (the "Issuer"), whose principal executive offices are located at 214 Carnegie Center, Suite 100, Princeton, New Jersey 08540.

Item 2. Identity and Background

This Schedule 13D is being filed by Edward J. Quilty (the "Reporting Person"). Certain information with respect to the Reporting Person is set forth below:

Name and Address: Edward J. Quilty

214 Carnegie Center

Suite 100

Princeton, NJ 08540

Principal Occupation: Chairman of the Board of Directors, President

and Chief Executive Officer of the Issuer

Criminal convictions: None

Civil proceedings: None

Citizenship: United States

Item 3. Source and Amount of Funds or Other Consideration

The issuance to the Reporting Person of the options to purchase common stock of the Issuer as described under Item 5 did not involve payment of consideration by the Reporting Person.

Item 4. Purposes of the Transactions

The purpose of the reported, and all previous, acquisitions of the Issuer's Common Stock, together with options to purchase same, is investment without a view, presently or ultimately, to acquiring control of the Issuer. The Reporting Person serves as Chairman of the Board of Directors, President and Chief Executive Officer of the Issuer. In this capacity, the Reporting Person has proposed, and may in the future propose, candidates for election to the Issuer's board of directors.

There is no agreement or arrangement between the Reporting Person and the Issuer with respect to election of candidates proposed by the Reporting Person. The inclusion of such candidates in management's slate of directors to be submitted for consideration by the Issuer's shareholders is entirely at the discretion of the Issuer's board of directors.

CUSIP No. 249827205 Schedule 13D

Item 5. Interest in Securities of the Issuer

The following table sets forth shares of the Issuer's Common Stock as to which the Reporting Person maintains beneficial ownership. The Reporting Person maintains both voting power and dispositive power relative to all such shares:

Beneficial Common Stock Ownership

Owned outright	335,684
Exercisable options (1)	20,000
Exercisable options (2)	40,000
Exercisable options (3)	76,055
Exercisable options (4)	135,000
Exercisable options (5)	18,000
Exercisable options (6)	62,500
Exercisable options (7)	12,500
Exercisable warrants (8)	220,001
Total beneficially owned	919,740
-	======
Percentage of class beneficially owned	9.10%
7	

(1)	Exercisable	at.	\$4 00	ner	share	

⁽²⁾ Exercisable at \$5.63 per share.

On June 10, 2004 the Issuer and the Reporting Person entered into a stock option agreement, pursuant to authorization of the Issuer's board of directors granted February 24, 2004, whereby the Reporting Person was awarded options to purchase 300,000 shares of the Issuer's common stock at \$1.55 per share. The options were issued in recognition of the Reporting Person's services to the Issuer in his capacities as Chairman of the board of directors, President and Chief Executive Officer.

The options vest as follows: (1) to the extent of 12,500 shares, on June 14, 2003; (2) to the extent of 37,500 shares, at the rate of 12,500 shares each on February 24, 2005, February 24, 2006 and February 24, 2007; and (3) to the extent of 250,000 shares, in accordance with performance objectives as determined by the board of directors of the Issuer.

The options were issued under the Issuer's stock option plan dated July 18, 1991, as amended, and are intended to qualify as incentive stock options. The options expire on February 23, 2014.

PAGE 5 CUSIP No. 249827205

Schedule 13D

Item 6. Contracts, Arrangements, Understandings or Relationships with respect to

⁽³⁾ Exercisable at \$5.93 per share.

⁽⁴⁾ Exercisable at \$0.40 per share.

⁽⁵⁾ Exercisable at \$0.61 per share.

⁽⁶⁾ Exercisable at \$0.37 per share.

⁽⁷⁾ Exercisable at \$1.55 per share.

⁽⁸⁾ Exercisable at \$0.85 per share.

Securities of the Issuer

None.

Item 7. Material to Be Filed as Exhibits

None.

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

/s/ Edward J. Quilty
-----By: Raymond C. Hedger, Jr.

June 11, 2004

POWER OF ATTORNEY INCORPORATED BY REFERENCE

Attorney-in-Fact

The limited power of attorney dated September 11, 2000 and filed with the Securities and Exchange Commission on September 11, 2000 with Edward J. Quilty's Schedule 13D/A, Amendment No. 4, is incorporated herein by reference